Stock Track | Ventyx Biosciences Soars 36.72% Intraday as Eli Lilly Eyes $1 Billion Acquisition

Stock Track01-07

Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 36.72% during intraday trading on Wednesday, following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion.

The Wall Street Journal reported that Eli Lilly is nearing a deal to purchase Ventyx, a clinical-stage biotechnology company developing oral therapies for inflammatory diseases such as Crohn's disease and rheumatoid arthritis. The potential acquisition would significantly expand Lilly's portfolio in autoimmune and obesity-related treatments.

Ventyx's pipeline includes mid-stage clinical trials for cardiovascular disease linked to obesity, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101984057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101984057","market":"sg","top_or_hot":-1,"title":"Stock Track | Ventyx Biosciences Soars 36.72% Intraday as Eli Lilly Eyes $1 Billion Acquisition","media":"Stock Track","content":"<p>Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 36.72% during intraday trading on Wednesday, following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion.</p><p>The Wall Street Journal reported that Eli Lilly is nearing a deal to purchase Ventyx, a clinical-stage biotechnology company developing oral therapies for inflammatory diseases such as Crohn's disease and rheumatoid arthritis. The potential acquisition would significantly expand Lilly's portfolio in autoimmune and obesity-related treatments.</p><p>Ventyx's pipeline includes mid-stage clinical trials for cardiovascular disease linked to obesity, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ventyx Biosciences Soars 36.72% Intraday as Eli Lilly Eyes $1 Billion Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ventyx Biosciences Soars 36.72% Intraday as Eli Lilly Eyes $1 Billion Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-07 23:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 36.72% during intraday trading on Wednesday, following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion.</p><p>The Wall Street Journal reported that Eli Lilly is nearing a deal to purchase Ventyx, a clinical-stage biotechnology company developing oral therapies for inflammatory diseases such as Crohn's disease and rheumatoid arthritis. The potential acquisition would significantly expand Lilly's portfolio in autoimmune and obesity-related treatments.</p><p>Ventyx's pipeline includes mid-stage clinical trials for cardiovascular disease linked to obesity, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTYX","symbol_name":"Ventyx Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1101984057","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101984057","pubTimestamp":1767798752,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 36.72% during intraday trading on Wednesday, following reports that Eli Lilly is in advanced talks to acquire the company for over $1...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTYX":"Ventyx Biosciences, Inc."},"translate_title":"个股追踪|Ventyx Biosciences盘中大涨36.72%礼来着眼于10亿美元收购","themeId":"77fb275fa4af0a1883523469f5f5adba","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTYX":1},"content_text":"Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 36.72% during intraday trading on Wednesday, following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion.The Wall Street Journal reported that Eli Lilly is nearing a deal to purchase Ventyx, a clinical-stage biotechnology company developing oral therapies for inflammatory diseases such as Crohn's disease and rheumatoid arthritis. The potential acquisition would significantly expand Lilly's portfolio in autoimmune and obesity-related treatments.Ventyx's pipeline includes mid-stage clinical trials for cardiovascular disease linked to obesity, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101984057","isCrawlerRequest":true}